Coral Laboratories Limited (524506) Fair Value & Analysis
Healthcare · IN · Market cap ₹1.4B
Fair value as of: Jul 4, 2026
From 14 valuation models · updated today
Share price +18.7% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹362.05 – ₹647.80 · fair‑value band ₹546.40 – ₹974.37 · the ₹605.55 price screens below the ₹779.49 fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Coral Laboratories Limited (524506) currently trades at ₹605.55, while our model-based Fair Value estimate is ₹779.49 — implying the stock looks roughly 28.7% undervalued today. We read business quality at 54/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
Over the trailing twelve months, Coral Laboratories Limited generated revenue of ₹792M at a net margin of 15.2%. Revenue grew 63.5% year over year. Net debt stands at ₹29.6M. The stock trades on a trailing P/E of 11.1. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Coral Laboratories Limited manufactures and sells pharmaceutical formulations in India, Ethopia, and internationally. The company offers antibiotics/antibacterial products, including antifungal, antiemetic, analgesics/antipyretic/antiinflammatory, antispasmodic, anticold, antiallergic, antiasthmatic, antidiabetic, antiemetics, anthelmentic, thyroid, and antiprotozoal/antiamebic products; antimalarial drugs, antipsychotic drugs, gastro-intestinal drugs, kits, muscle relaxants, cough suppressant/expectorant products, cardiovascular medicines, oral antiseptic preparations, mouthwashes, calcium preparations, and appetizers; and nutritional, protein, and iron supplements, as well as other products. It also provides cephalosporin, beta lactam, and lyophilized injectable products; eye/ear/nose drops; nasal sprays and metered dose inhales; and large volume parenteral products. In addition, the company offers various nutraceutical products, such as dietary supplements, …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Coral Laboratories Limited reported revenue of ₹859M in FY2026 versus ₹756M in FY2022, a compound +3.2%/yr. Reported net income was ₹164M in FY2026, compounding +16.0%/yr from FY2022.
Is 524506 fairly valued? → Check now
Similar stocks
6 more Drugs - Generic stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Indoco Remedies Limited 532612 | ₹244.55 | ₹96.79 | -60% |
| Anuh Pharma Limited 506260 | ₹80.21 | ₹110.37 | +38% |
| Medicamen Biotech Limited 531146 | ₹262.00 | ₹98.91 | -62% |
| Gennex Laboratories Limited 531739 | ₹10.16 | ₹28.19 | +177% |
| Lactose (India) Limited 524202 | ₹103.75 | ₹130.91 | +26% |
| Beryl Drugs Limited 524606 | ₹21.22 | ₹17.12 | -19% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Coral Laboratories Limited (524506) undervalued?
What is the fair value of 524506?
What is the quality score of 524506?
What is the revenue of Coral Laboratories Limited (524506)?
What is the net profit margin of 524506?
Does Coral Laboratories Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.